Anavex Life Sciences Corp. (NASDAQ:AVXL) was down 4.5% on Tuesday . The company traded as low as $6.90 and last traded at $7.04, with a volume of 806,566 shares changing hands. The stock had previously closed at $7.37.

A number of equities research analysts have weighed in on AVXL shares. Maxim Group reaffirmed a “buy” rating and set a $15.00 price objective on shares of Anavex Life Sciences Corp. in a report on Wednesday, June 22nd. FBR & Co reaffirmed a “buy” rating on shares of Anavex Life Sciences Corp. in a report on Wednesday, June 22nd. Finally, Zacks Investment Research raised Anavex Life Sciences Corp. from a “hold” rating to a “buy” rating and set a $5.00 price objective on the stock in a report on Tuesday, May 31st.

The firm’s market cap is $254.17 million. The company has a 50-day moving average of $5.41 and a 200 day moving average of $4.84.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last issued its earnings results on Wednesday, May 11th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.10. On average, analysts anticipate that Anavex Life Sciences Corp. will post ($0.34) earnings per share for the current fiscal year.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.